We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets close in 1 hr 30 mins

IsoRay, Inc. (ISR)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4604+0.0052 (+1.14%)
As of 2:12PM EDT. Market open.
Full screen
Previous Close0.4552
Open0.4400
Bid0.0000 x 1000
Ask0.0000 x 1000
Day's Range0.4400 - 0.4614
52 Week Range0.3600 - 0.6500
Volume54,168
Avg. Volume246,362
Market Cap25.368M
Beta1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.1130
Earnings DateFeb 9, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.55
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    IsoRay Announces Entry into Employment Agreement with Lori A. Woods as Interim CEO

    Richland, Wash., June 19, 2018 (GLOBE NEWSWIRE) --  – IsoRay, Inc. (NYSE American: ISR) (the “Company”), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, is pleased to announce that it has entered into a one-year employment contract with Lori A. Woods, as Interim Chief Executive Officer and as a Director on the Company’s Board of Directors.  Lori Woods was appointed Interim CEO and as a director effective as of June 4, 2018. Chairman of the Board Mick McCormick stated, “The Board and employees have high confidence in Lori Woods that has been built through the years that she has served at IsoRay.

  • GlobeNewswire17 days ago

    IsoRay Announces the Resignation of Chairman and CEO Thomas LaVoy; Industry Veteran Lori Woods Appointed Interim CEO; Mick McCormick Appointed Chairman of the Board

    IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that Thomas LaVoy has resigned from his positions as Chairman of the Board and Chief Executive Officer of the Company, effective as of June 4, 2018.  Mr. LaVoy had been a Director of the Company since 2005.  He was appointed Chairman of the Board in January 2016 and took office as Chief Executive Officer of the Company on February 15, 2016.

  • ACCESSWIRE22 days ago

    IsoRay to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...

  • GlobeNewswire23 days ago

    IsoRay Announces Signing of Research Funding with Ochsner Clinic Foundation to Support Brain Cancer Treatment Research

    The funding is intended to support a study entitled “Comparison of Minimally Invasive Keyhole Craniotomy and Stereotactic Radiosurgery for the Treatment of New Brain Oligometastases: A Prospective, Open Label Study”.  The study will be led by Dr. Marcus Ware M.D., Ph.D., Medical Director of Neurosurgical Oncology at Ochsner. Dr. Ware is a Harvard Medical School graduate who completed his residency at the University of California, San Francisco, one of the premiere programs in the world in brain tumor surgery and neuro-oncology. At Ochsner, he specializes in the treatment of primary and metastatic brain tumors.

  • When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?
    Simply Wall St.28 days ago

    When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?

    IsoRay Inc’s (AMEX:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • ACCESSWIRElast month

    IsoRay, Inc. Discusses Competitive Landscape, FDA Clearance for New Product Line and Growth Drivers in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Tom LaVoy, Chairman of the Board & CEO of IsoRay, Inc. ...

  • Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately
    Simply Wall St.last month

    Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately

    For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at IsoRay Inc’sRead More...

  • GlobeNewswirelast month

    IsoRay Announces Participation at the American Urological Association’s 2018 Annual Meeting, May 18-21, 2018

    RICHLAND, Wash., May 16, 2018 (GLOBE NEWSWIRE) --  IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the Company’s participation at the upcoming American Urological Association (AUA) Annual Meeting, taking place on May 18-21, 2018 in San Francisco, CA. “The AUA is one of our biggest opportunities each year to share the latest information about brachytherapy with the urological community,” said Thomas LaVoy, Chairman and Chief Executive Officer of IsoRay, Inc. “We believe that Cesium-131, with its unique fast energy delivery and quick patient recovery, provides urologists with a better option for their prostate cancer patients.  Dr. Benoit is a long-time researcher and advocate of Cesium-131 and we’re pleased that his participation on the prostate cancer panel will ensure that this important information is correctly presented to the urological community.

  • GlobeNewswirelast month

    IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment

    IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the upcoming release of its Build-Blu™ delivery system for real-time prostate brachytherapy. The Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room, thereby allowing clinicians to individualize the procedure to the patient’s anatomy in real time.  This new product will provide an alternative solution to the approximately 25% of treatment facilities for the prostate market that are using intra-operative techniques.

  • Associated Press2 months ago

    IsoRay: Fiscal 3Q Earnings Snapshot

    The Richland, Washington-based company said it had a loss of 2 cents per share. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of trading on ...